JP2021517457A5 - - Google Patents

Download PDF

Info

Publication number
JP2021517457A5
JP2021517457A5 JP2020548645A JP2020548645A JP2021517457A5 JP 2021517457 A5 JP2021517457 A5 JP 2021517457A5 JP 2020548645 A JP2020548645 A JP 2020548645A JP 2020548645 A JP2020548645 A JP 2020548645A JP 2021517457 A5 JP2021517457 A5 JP 2021517457A5
Authority
JP
Japan
Prior art keywords
seq
region
amino acid
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020548645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021517457A (ja
JP7209008B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/056197 external-priority patent/WO2019175198A2/en
Publication of JP2021517457A publication Critical patent/JP2021517457A/ja
Publication of JP2021517457A5 publication Critical patent/JP2021517457A5/ja
Priority to JP2022143428A priority Critical patent/JP7447208B2/ja
Application granted granted Critical
Publication of JP7209008B2 publication Critical patent/JP7209008B2/ja
Priority to JP2024027970A priority patent/JP7791229B2/ja
Priority to JP2025245068A priority patent/JP2026041981A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020548645A 2018-03-12 2019-03-12 抗体 Active JP7209008B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022143428A JP7447208B2 (ja) 2018-03-12 2022-09-09 抗体
JP2024027970A JP7791229B2 (ja) 2018-03-12 2024-02-28 抗体
JP2025245068A JP2026041981A (ja) 2018-03-12 2025-12-11 抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18161293.8 2018-03-12
EP18161293 2018-03-12
EP18175347 2018-05-31
EP18175347.6 2018-05-31
PCT/EP2019/056197 WO2019175198A2 (en) 2018-03-12 2019-03-12 Antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022143428A Division JP7447208B2 (ja) 2018-03-12 2022-09-09 抗体

Publications (3)

Publication Number Publication Date
JP2021517457A JP2021517457A (ja) 2021-07-26
JP2021517457A5 true JP2021517457A5 (cg-RX-API-DMAC7.html) 2021-10-07
JP7209008B2 JP7209008B2 (ja) 2023-01-19

Family

ID=65729373

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020548645A Active JP7209008B2 (ja) 2018-03-12 2019-03-12 抗体
JP2022143428A Active JP7447208B2 (ja) 2018-03-12 2022-09-09 抗体
JP2024027970A Active JP7791229B2 (ja) 2018-03-12 2024-02-28 抗体
JP2025245068A Pending JP2026041981A (ja) 2018-03-12 2025-12-11 抗体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022143428A Active JP7447208B2 (ja) 2018-03-12 2022-09-09 抗体
JP2024027970A Active JP7791229B2 (ja) 2018-03-12 2024-02-28 抗体
JP2025245068A Pending JP2026041981A (ja) 2018-03-12 2025-12-11 抗体

Country Status (20)

Country Link
US (5) US20200277397A1 (cg-RX-API-DMAC7.html)
EP (1) EP3765493A2 (cg-RX-API-DMAC7.html)
JP (4) JP7209008B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200130723A (cg-RX-API-DMAC7.html)
CN (2) CN120795158A (cg-RX-API-DMAC7.html)
AU (2) AU2019233523B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020018490A2 (cg-RX-API-DMAC7.html)
CA (1) CA3093745A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002326A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020012524A2 (cg-RX-API-DMAC7.html)
CR (3) CR20200463A (cg-RX-API-DMAC7.html)
EC (1) ECSP20063690A (cg-RX-API-DMAC7.html)
IL (1) IL277030A (cg-RX-API-DMAC7.html)
MA (1) MA52152A (cg-RX-API-DMAC7.html)
MX (7) MX2020009379A (cg-RX-API-DMAC7.html)
PE (1) PE20210339A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551447A1 (cg-RX-API-DMAC7.html)
SA (3) SA523440623B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202008399QA (cg-RX-API-DMAC7.html)
WO (1) WO2019175198A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102813816B1 (ko) * 2013-07-05 2025-05-29 젠맵 에이/에스 인간화 또는 키메라 cd3 항체
FI3322727T3 (fi) 2015-07-15 2026-03-17 Genmab As Humanisoituja tai kimeerisiä CD3-vasta-aineita
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
MA52152A (fr) 2018-03-12 2021-01-20 Genmab As Anticorps
US12674001B2 (en) 2019-09-12 2026-07-07 Genmab A/S Method of treating cancer by administering an antibody which binds to 5T4
EP4210752A4 (en) * 2020-09-11 2025-09-24 Actinium Pharmaceuticals Inc Trophoblastic Glycoprotein Radiation Immunotherapy for the Treatment of Solid Cancers
CA3202891A1 (en) 2021-01-28 2022-08-04 Kara Olson Compositions and methods for treating cytokine release syndrome
MX2023013018A (es) * 2021-05-04 2024-01-18 Immunorizon Ltd Anticuerpos anti-5t4 y usos de estos.
WO2023107954A1 (en) * 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
AU2023254191A1 (en) 2022-04-11 2024-10-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
US20260167739A1 (en) * 2022-11-08 2026-06-18 Phanes Therapeutics, Inc. Anti-5t4 antibodies and uses thereof
AU2024223918A1 (en) 2023-02-17 2025-09-11 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
PT1012259E (pt) 1997-06-04 2009-11-06 Oxford Biomedica Ltd Vector dirigido a tumor
US6355271B1 (en) 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
JP2003515323A (ja) 1999-11-18 2003-05-07 オックスフォード バイオメディカ(ユーケイ)リミテッド 抗 体
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
GB0126378D0 (en) 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
CA2578131A1 (en) * 2004-09-10 2006-03-23 Wyeth Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 1가 항체 및 그의 제조 방법
SG170091A1 (en) * 2006-03-10 2011-04-29 Wyeth Corp Anti-5t4 antibodies and uses thereof
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
JP5397668B2 (ja) 2008-09-02 2014-01-22 ソニー株式会社 記憶素子および記憶装置
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス,インコーポレーテッド 共有結合型ダイアボディ及びその使用
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
GB0918383D0 (en) 2009-10-20 2009-12-02 Cancer Rec Tech Ltd Prognostic,screening and treatment methods and agents for treatment of metastasis and inflammation
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗-vegf/抗-ang-2抗體
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
IL299365A (en) 2010-05-27 2023-02-01 Genmab As Monoclonal antibodies against 2HER
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
BR112013002167A2 (pt) 2010-08-24 2016-05-31 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
MX2014003313A (es) * 2011-09-23 2014-07-09 Amgen Res Munich Gmbh Moleculas de union biespecificas para 5t4 y cd3.
IN2014CN03887A (cg-RX-API-DMAC7.html) 2011-10-27 2015-10-16 Genmab As
WO2014006217A1 (en) 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
WO2014137931A1 (en) 2013-03-06 2014-09-12 Imaginab, Inc. Antigen binding constructs to 5t4
KR102813816B1 (ko) 2013-07-05 2025-05-29 젠맵 에이/에스 인간화 또는 키메라 cd3 항체
WO2015155345A1 (en) * 2014-04-11 2015-10-15 Medimmune Limited Antibodies and antibody-drug conjugates
WO2016022939A1 (en) * 2014-08-08 2016-02-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies specific for 5t4 and methods of their use
MX384198B (es) 2014-12-19 2025-03-14 Chiome Bioscience Inc Proteina de fusion que comprende tres dominios de union a 5t4 y cd3.
FI3322727T3 (fi) 2015-07-15 2026-03-17 Genmab As Humanisoituja tai kimeerisiä CD3-vasta-aineita
HK1258306A1 (zh) 2015-10-29 2019-11-08 F. Hoffmann-La Roche Ag 具有共同轻链的转基因兔
EP3184547A1 (en) * 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
KR20180083425A (ko) * 2015-11-24 2018-07-20 신톤 바이오파머슈티칼즈 비.브이. 항-5t4 항체 및 항체-약물 접합체
CN110698559B (zh) * 2015-12-24 2021-11-26 凯惠科技发展(上海)有限公司 一种tpbg抗体及其制备方法、其偶联物和应用
BR112018071612A2 (pt) * 2016-04-22 2019-02-19 Alligator Bioscience Ab polipeptídeos biespecíficos inovadores contra cd137
CN108285487B (zh) 2017-01-08 2021-02-19 浙江昭华生物医药有限公司 抗5t4抗体-药物偶联物及其应用
EP3595705A1 (en) 2017-03-15 2020-01-22 Oxford BioMedica (UK) Limited Method
WO2018184558A1 (zh) 2017-04-05 2018-10-11 凯惠科技发展(上海)有限公司 一种人源化抗tpbg抗体及其制备方法、其偶联物和应用
US11725060B2 (en) 2017-07-20 2023-08-15 Aptevo Reserch and Development LLC Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods
US20220267403A1 (en) 2017-12-01 2022-08-25 Fred Hutchinson Cancer Research Center Binding proteins specific for 5t4 and uses thereof
CN111787949A (zh) 2018-02-15 2020-10-16 宏观基因有限公司 变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途
MA52152A (fr) 2018-03-12 2021-01-20 Genmab As Anticorps
US12674001B2 (en) * 2019-09-12 2026-07-07 Genmab A/S Method of treating cancer by administering an antibody which binds to 5T4

Similar Documents

Publication Publication Date Title
JP2021534779A (ja) 抗体構築物がプレロードされた凍結保存nk細胞
JP2020504171A (ja) 抗PD−1抗体との組み合わせのための抗Tim−3抗体
WO2020114478A1 (zh) Cd3抗体及其药物用途
EP3882276A1 (en) Bispecific antibody, preparation method therefor and application thereof
JP2018531219A6 (ja) Pd−l1抗体
JP2018531219A (ja) Pd−l1抗体
JP2023517753A5 (cg-RX-API-DMAC7.html)
WO2020114479A1 (zh) 多特异性蛋白分子
JP2023513200A (ja) 抗cd3および抗cd123二重特異性抗体およびその使用
CN112166125B (zh) 全人源的抗lag-3抗体及其应用
KR20230074192A (ko) 인간 cd3 엡실론에 결합하는 신규의 인간 항체
CN121758618A (zh) Pd1和vegfr2双结合剂
CN112771075A (zh) 结合至cd33和cd3的双特异性抗体构建体的延长施用
US20230312709A1 (en) Antibody targeting CD47 and application thereof
CN119095873A (zh) 用于靶向杀伤GPC3阳性恶性细胞的双特异性GPC3xCD28和GPC3xCD3抗体及其组合
CN119060184B (zh) 抗rage抗体及其应用
WO2024012434A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
EP4703384A1 (en) Bispecific antibody targeting g protein-coupled receptor
US20240376208A1 (en) Duplexbodies
CN115368457A (zh) 抗tigit抗体及其用途
Zettlitz et al. Humanization of a mouse monoclonal antibody directed against a cell surface-exposed epitope of membrane-associated heat shock protein 70 (Hsp70)
JP2022547135A (ja) 増強されたプロテインl捕捉動的結合容量を有する二重特異性抗原結合ポリペプチドの精製方法
CN119371542B (zh) 抗rage抗体及其应用
JP7844430B2 (ja) 抗gprc5d抗体に対する抗イディオタイプ抗体
US20240376196A1 (en) Cd112 antibody and use